Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time

Rhea-AI Summary

Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced it will report its financial results for Q4 and FY 2022 on March 30, 2023, post-market. The conference call will start at 4:30 p.m. ET, with a new registration process for participants. Lisata is a clinical-stage company focused on developing innovative therapies for advanced solid tumors. Its lead product, LSTA1, aims to enhance the delivery of anti-cancer drugs to tumors while sparing normal tissues, showing promising results in pancreatic cancer trials. Lisata continues to explore LSTA1 for various solid tumors, alongside its autologous CD34+ cell therapy technology.

Positive

• LSTA1 shows favorable safety and activity in pancreatic cancer clinical trials.
• LSTA1 may enhance delivery of various anti-cancer therapies including immunotherapies and RNA-based treatments.

Negative

• None.

BASKING RIDGE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the three and twelve months ended December 31, 2022, on Thursday, March 30, 2023, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.

The Company is utilizing a new conference call service. Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details for dial-in options. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

A live webcast of the call will also be accessible under the Investors & News section of the Company’s website and will be available for replay beginning two hours after the conclusion of the call for 12 months.

About Lisata Therapeutics

Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead investigational product candidate, LSTA1 (formerly known as CEND-1), LSTA1 is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (“TME”), with the objective of making tumors more susceptible to immunotherapies LSTA1 has demonstrated favorable safety, tolerability, and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, Lisata has clinical development programs based on its autologous CD34+ cell therapy technology platform. For more information on the Company, please visit www.lisata.com.

Contact:

Investors and Media:

Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com

FAQ

What are the upcoming financial results for Lisata Therapeutics (LSTA)?

Lisata Therapeutics will report its financial results for the three and twelve months ended December 31, 2022, on March 30, 2023.

When will Lisata Therapeutics (LSTA) hold its conference call?

The conference call for Lisata Therapeutics is scheduled for March 30, 2023, at 4:30 p.m. Eastern time.

How can I participate in the Lisata Therapeutics (LSTA) conference call?

Participants must register for the conference call using the provided registration link. A live webcast will also be available on the company's website.

What is the purpose of Lisata's LSTA1 therapy?

LSTA1 is designed to enhance the penetration of anti-cancer drugs into solid tumors, improving treatment effectiveness while limiting damage to normal tissues.

What types of cancer is Lisata Therapeutics (LSTA) targeting?

Lisata Therapeutics is focusing on advanced solid tumors, particularly pancreatic cancer, and exploring treatments for a variety of solid tumors.